Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.34 |
| ▸ | PTAFR | P25105 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534289 | 0.85 | REN (0.41) | RENKCNH2APLNR | |
| SCHEMBL534916 | 0.82 | REN (0.54) | RENKCNH2APLNR | |
| SCHEMBL556315 | 0.82 | REN (0.40) | RENKCNH2MMP8MMP13 | |
| SCHEMBL535102 | 0.81 | REN (0.36) | RENKCNH2MMP8MMP13APLNR | |
| SCHEMBL557571 | 0.80 | REN (0.41) | RENKCNH2APLNRPTAFR | |
| SCHEMBL533878 | 0.78 | REN (0.54) | RENKCNH2 | |
| SCHEMBL10202445 | 0.77 | REN (0.60) | RENKCNH2 | |
| SCHEMBL555467 | 0.77 | REN (0.61) | RENKCNH2 | |
| SCHEMBL556668 | 0.77 | LIPE (0.36) | RENKCNH2CHRM3 | |
| SCHEMBL556180 | 0.73 | REN (0.38) | RENAPLNRKDM4EHSD17B10CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1198/4885MMP8 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.